face substantial competition.
•
Our intellectual property positions may be challenged, invalidated or circumvented, or we may fail to prevail in current and future intellectual property litigation.
•
We currently face competition from biosimilars and generics and expect to face increasing competition from biosimilars and generics in the future.
•
Concentration of sales at certain of our wholesaler distributors, and consolidation of private payers, such as insurers, and PBMs has negatively affected, and may continue to negatively affect, our business.
Risks Related to Research and Development
•
We may not be able to develop commercial products despite significant investments in R&D.
•
We must conduct clinical trials in humans before we commercialize and sell any of our product candidates or existing products for new indications.
•
Our current products and products in development cannot be sold without regulatory approval.
•
Some of our products are used with drug delivery or companion diagnostic devices that have their own regulatory, manufacturing and other risks.
28
•
Some of our pharmaceutical pipeline and our commercial product sales rely on collaborations with third parties, which may adversely affect the development and sales of our products.
Risks Related to Operations
•
We perform a substantial majority of our commercial manufacturing activities at our facility in the U.S. territory of Puerto Rico and a substantial majority of our clinical manufacturing activities at our facility in Thousand Oaks, California; significant disruptions or production failures at these facilities could significantly impair our ability to supply our products or continue our clinical trials.
•
We rely on third-party suppliers for certain of our raw materials, medical devices and components.
•
Manufacturing difficulties, disruptions or delays could limit supply of our products and limit our product sales.
•
Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives.
•
The effects of global climate change and related natural disasters could negatively affect our business and operations.
General Risk Factors
•
Global economic conditions may negatively affect us and may magnify certain risks that affect our business.
•
Our stock price is volatile.
RISKS RELATED TO GOVERNMENT REGULATIONS AND THIRD-PARTY POLICIES
Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, our profitability.
Sales of our products depend on the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans. Governments and private payers continue to pursue initiatives to manage drug utilization and contain costs. Further, pressures on healthcare budgets from the economic